- Conditions
- Leukemia
- Interventions
- filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, idarubicin, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 51
- States / cities
- Tucson, Arizona • Palo Alto, California • Sacramento, California + 44 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–37
of 13
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lymphoma
- Interventions
- asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2015
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- Asparaginase, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Filgrastim, Hydrocortisone Sodium Succinate, Ifosfamide, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisone, Radiation Therapy, Vincristine Sulfate
- Drug · Biological · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 118
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 94 more
- Conditions
- Leukemia
- Interventions
- asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, thioguanine, vincristine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 18 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 50
- States / cities
- Tucson, Arizona • Palo Alto, California • Sacramento, California + 43 more
- Conditions
- Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm, Myeloid Sarcoma
- Interventions
- Asparaginase, Bortezomib, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration, Sorafenib Tosylate
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 29 Years
- Enrollment
- 1,645 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 195
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
- Conditions
- Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase, Allergy to Native e.Coli Asparaginase
- Interventions
- Erwinase, Vincristine, Dexamethasone, Doxorubicin, Cytarabine, Methotrexate, Triple Intrathecal Therapy, Dexrazoxane
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 211
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more
- Conditions
- Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab, Standard of Care Chemotherapy
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 16
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Calaspargase Pegol, Levocarnitine, Pegaspargase, Quality-of-Life Assessment
- Procedure · Drug · Dietary Supplement + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 225
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 149 more
- Conditions
- Leukemia
- Interventions
- asparaginase, cytarabine, daunorubicin hydrochloride, etoposide, gemtuzumab ozogamicin, mitoxantrone hydrochloride
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 1,070 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2020
- U.S. locations
- 178
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 141 more
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia
- Interventions
- IM JZP-458, IV JZP-458
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
- Conditions
- Adult Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Downey, California + 36 more
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Recurrent T Lymphoblastic Leukemia/Lymphoma, Refractory B Lymphoblastic Lymphoma, Refractory T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
- Interventions
- Asparaginase, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Imatinib Mesylate, Laboratory Biomarker Analysis, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Other · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington